CATEGORY : Clinical Diagnostics

Life Science Market Reports

Our life science market intelligence products have been recognized by market insiders and outsiders alike for their accuracy, in-depth analysis, and unique insights.

Market Reports

Collaborative, Decentralized Research Drives Liquid Biopsy Advances – AGBT 2020

  For AGBT 2020, we analyzed collaboration networks within liquid biopsy publications to understand the landscape. We analyzed ~2,600 liquid biopsy publications 1, indexing ~1,300 affiliations and ~15,000 authors in 60

Supplying the COVID Demand — How Dx Behemoths and Tele-Diagnostics Entrants Aim to Close the Gap

  As more COVID-19 diagnostics win FDA emergency use authorization, weekly commercial production capacity is expected to hit 6.5M+ tests; telehealth providers attempt to jump into the fray, but are

A 2020 Look at 3 Trends in Immuno-Oncology Biomarkers

We recently added >300 new trials to our I/O biomarker clinical trial tracker, The I/O BioMAP, bringing our running total to ~2,700 studies, and providing new data that sheds light

How KKR Made a ~3x Return in 4 Years by Investing in Research Tools

  KKR made headlines late last year with the exit of their investment in LGC Group, a UK-based biochemical standards and reagents provider. Sources say KKR acquired LGC in December

Going Viral: What the COVID-19 Outbreak Teaches Us About the Evolution of the Biotech Industry

  The novel coronavirus (COVID-19) outbreak has been a huge topic of concern across the globe as infection and death tolls continue to grow daily. However, it’s inarguable that the

Evolution in the precision oncology landscape – Part 2 (Therapeutic Developments)

Over the past several months, we spoke to experts across the precision medicine landscape to understand some of the key changes and most impactful scenarios they expect in this space.

3 Machine Learning / Artificial Intelligence Trends In The Diagnostics Space For 2020 And Beyond

2019 was another strong year for machine learning and artificial intelligence within the diagnostic space, and the acceleration of progress in ML / AI is clearly going to continue within

Select 2019 Trends and Discussions

  Los Angeles, CA January 3, 2019 – The end the last decade deepened my personal belief that the personalized medicine revolution will be driven by tools and diagnostics, rather

QIAGEN to Become Thermo?

In mid-November, speculation began that ThermoFisher was in talks with QIAGEN surrounding a potential acquisition. A hypothetical tie-up could help Thermo bolster its reach into clinical diagnostic tests and nucleic